Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101
Become a patient

A/Prof David Pryor

BSc, MBBS, FRANZCR

  • Radiation Oncologist
Become a patient Refer a patient
Greenslopes
07 3099 8400 07 3099 8401
admin.greenslopes@icon.team

Biography

A/Prof David Pryor is an experienced radiation oncologist Icon Cancer Centre Greenslopes and Icon Cancer Centre Redland. He specialises in the management of urological cancer, gastrointestinal cancer, thoracic cancer, soft tissue sarcoma and skin cancers and the use of highly focused stereotactic radiation therapy and palliative radiotherapy.

He is committed to providing high quality cancer care and believes in driving education, quality improvement, research and innovation through his leadership roles in Icon Cancer Centre’s stereotactic radiation therapy network, Adjunct Associate Professor at the Queensland University of Technology, senior lecturer with the University of Queensland, chair of the QLD steering committee for the Prostate Cancer Outcomes Registry (PCOR-ANZ) and immediate past chair of the Genitourinary Committee of the Trans-Tasman Radiation Oncology Group (TROG). He is the national co-chair of studies evaluating the role of stereotactic radiotherapy in the management of oligometastatic cancers and in early-stage liver cancer and a member of the trial management committee for numerous other collaborative group trials in prostate, bladder, kidney, gastrointestinal and soft tissue tumours.

Publications

  • Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review. H. Liu, Y. Lee, S. Sridharan, E. Choong, H. Le, W. Wang, R. Khor, J. Chu, A. Oar, R. Mott, J. Smart, T. Jenkins, N. Anderson, S. Cross, K. Loo, A. Wigg, K. Stuart, & D. Pryor. Journal of medical imaging and radiation oncology, 2021; 65(3), 365–373.

Research

Trials being conducted by this doctor

PIVOTAL

The use of Restorabite will be offered to participants for the treatment of trismus after head and neck cancer surgery in place of other standard of care devices such as Ark-J (stacked wooden tongue depressor) or TheraBite.Restorabite is a mass produced and non-custom made device, however, participants will be assigned to a specific insert by treating speech pathologist and surgeon depending on the severity of trismus and the recovery from the surgery. Participants will be asked to be involved with following interventions.|— a) Passive jaw range of motion exercises using Restorabite.|— b) Active jaw range of motion exercises using Restorabite.|— c) 10 x 1hr weekly sessions face to face at speech pathology clinic at hospital or over telehealth with speech pathology with minimum 3 years’ experience. Gradual progression through the force hierarchy as clinically indicated.|— d) Home practice: daily for 20 minutes for duration of study (10 weeks).|— e) Measurement of Interincisal distance at baseline, at the end of 10 x weekly sessions, 6 months and 12 months follow up appointment.Passive and active jaw range of motion exercises is a continuous exercise performed with Restorabite. It involves inserting the pressed down Restorabite between the front teeth and letting the device stretch the jaw (passive motion exercise) then bite down on the mouth guards (active motion exercise). Then repeat the letting go of the bite (passive motion exercise) and biting down on the device (active motion exercise). During the 1 hour weekly session, speech pathologist will determine how many repetitions should be carried out and recommend the duration of each exercise (i.e., Hold the passive action for 1 minute then hold the active action for 1 minute. Repeat 10 times). Participants will be asked to carry out a personalised exercise regime as home practice every day.During the 1 hour weekly session, speech pathologist will determine the passive and active motion exercise regime for coming week. Interincisal distance will be measured at the start of the session then participants will be asked to carry out the prescribed exercise regime. Interincisal distance will be measured at the end of the session to observe a change in interincisal distance.To monitor adherence to the intervention speech pathologists will closely follow up participants. To increase the adherence to the intervention, speech pathologists will set up a 10 week appointment plan at the beginning of the trial and also offer tele-health appointments.

Locations Adelaide

Diagnosis Head and neck cancer

Open for recruitment